Drug intelligence / Profile preview

ATGC-200

Development stage: Unknown
Lead developer: ATGC Co. Ltd
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

**ATGC-200** is an investigational fixed-dose injectable combination being developed by ATGC for osteoarthritis. It combines botulinum toxin with a hyaluronic acid injection-based osteoarthritis treatment. ATGC describes the intended product profile as combining botulinum toxin-associated suppression of pain-related mediators with hyaluronic acid-associated cartilage-protective effects; company-reported animal studies described anti-inflammatory and cartilage-protection activity relative to hyaluronic acid injection alone. ([atgcbio.com](https://atgcbio.com/pdf/atgc_159315474431.Business%20Report%28eng%29%20v3%20print_compressed.pdf))

Other names: ATGC 200ATGC200ATGC-200

Targets

SNAP25 (Synaptosome-associated protein 25)

Beyond the preview

Go deeper on ATGC-200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATGC-200.

Explore the full profile